Effect of pravastatin on impaired endothelium-dependent relaxation induced by lysophosphatidylcholine in rat aorta

Acta Pharmacologica Sinica

Volumn 26, Issue 1, 2005, Pages 92-98

  Deng, Hua Fei ^a   Xiong, Yan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

L arginine; Lysophosphatidylcholine; Nitric oxide; Pravastatin; Rats; Superoxide dismutase; Thoracic aorta; Vascular endothelium; Vasodilation

Indexed keywords

ACETYLCHOLINE; ARGININE; CHELERYTHRINE; INDOMETACIN; LYSOPHOSPHATIDYLCHOLINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PRAVASTATIN; PROSTAGLANDIN SYNTHASE; SUPEROXIDE DISMUTASE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM; ENDOTHELIUM INJURY; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PROTECTION; RAT; THORACIC AORTA; VASCULAR RING; VASODILATATION;

ALKALOIDS; ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA, THORACIC; ARGININE; BENZOPHENANTHRIDINES; ENDOTHELIUM, VASCULAR; FREE RADICAL SCAVENGERS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYSOPHOSPHATIDYLCHOLINES; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PHENANTHRIDINES; PRAVASTATIN; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 11844284834     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00013.x     Document Type: Article

References (29)

1. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-95.
2. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-2.
3. Mangin EL Jr, Kugiyama K, Nguy JH, Kerns SA, Henry PD. Effects of lysolipids and oxidatively modified low density lipoprotein on relaxation of rabbit aorta. Circ Res 1993; 72: 161-6.
4. Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG. Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. Arterioscler Thromb 1994; 14: 1007-13.
5. Koizumi J, Shimizu M, Miyamoto S, Origasa H, Mabuchi H. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT). J Atheroscler Thromb 2002; 9: 251-9.
6. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002; 106: 2884-7.
7. Ma FX, Liu LY, Xiong XM. Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein. Acta Pharmacol Sin 2003; 24: 1027-32.
8. Jiang JL, Jiang DJ, Tang YH, Li NS, Deng HW, Li YJ. Effect of simvastatin on endothelium-dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 2004; 25: 893-901.
9. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31: 2442-9.
10. Sindermann JR, Fan L, Weigel KA, Troyer D, Muller JG, Schmidt A, et al. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis 2000; 150: 331-41.
11. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-45.
12. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003; 21: 379-86.
13. Kagota S, Yamaguchi Y, Nakamura K, Kunitomo M. Functional evidence for anti-oxidant action of fluvastatin on low-density lipoprotein using isolated macrophages and aorta. Clin Exp Pharmacol Physiol 2000; 27: 401-5.
14. Wagner AH, Kohler T, Ruckschloss U, Just L, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-9.
15. Yasunari K, Maeda K, Minami M, Yoshikawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001; 21: 937-42.
16. Wassman S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 93: 98-103.
17. Silva EP, Fonseca FA, Ihara SS, Izar MC, Lopes IL, Pinto LE, et al. Early benefits of pravastatin to experimentally induced atherosclerosis. J Cardiovasc Pharmacol 2002; 39: 389-95.
18. Kobayashi T, Matsumoto T, Kamata K. Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br J Pharmacol 2000; 131; 231-8.
19. Vuong TD, Kimpe SD, Roos RD, Rabelink TJ, Koomans HA, Joles JA. Albumin restores lysophosphatidylcholine-induced inhibition of vasodilation in rat aorta. Kidney Int 2001; 60: 1088-96.
20. Murohara T, Kugiyama K, Ota Y, Doi H, Ogata N, Ohgushi M, et al. Effects of atrial and brain natriuretic peptides on lysophosphatidylcholine-mediated endothelial dysfunction. J Cardiovasc Pharmacol 1999; 34: 870-8.
21. Kikuta K, Sawamura T, Miwa S, Hashimoto N, Masaki T. High-affinity arginine transport of bovine aortic endothelial cells is impaired by lysophosphatidylcholine. Circ Res 1998; 83: 1088-96.
22. Hague W, Forder P, Simes J, Hunt D, Tonkin A: LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Am Heart J 2003; 145: 643-51.
23. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-41.
24. Thakur NK, Hayashi T, Sumi D, Kano H, Tsunekawa T, Iguchi A. HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide. Am J Physiol Heart Circ Physiol 2001; 281: H75-83.
25. Masumoto A, Hirooka Y, Hironaga K, Eshima K, Setoguchi S, Egashira K, et al. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001; 88: 1291-4.
26. Parker RA, Huang Q, Tesfamariam B. Influence of 3-hydroxy-3- methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis 2003; 169: 19-29.
27. Chen H, Xing Y, Liu RH. Lovastatin increases nitric oxide synthesis in IL-1β- stimulated smooth muscle cells. Chin Med J 2001; 114: 1123-7.
28. Bandoh T, Sato EF, Mitani H, Nakashima A, Hoshi K, Inoue M. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. Biol Pharm Bull 2003; 26: 818-22.
29. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-5.